<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04855786</url>
  </required_header>
  <id_info>
    <org_study_id>834599</org_study_id>
    <nct_id>NCT04855786</nct_id>
  </id_info>
  <brief_title>External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients</brief_title>
  <official_title>External Drainage of Thoracic Duct Lymph to Reduce Inflammatory Cytokines in Septic Shock Patients: A Pilot Trial With Concurrent Controls to Confirm Safety and Assess Preliminary Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Research Council, New Zealand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Auckland, New Zealand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that external drainage of thoracic duct lymph during sepsis results in a&#xD;
      reduction in circulating pro-inflammatory cytokines.&#xD;
&#xD;
      To demonstrate safety and feasibility of early thoracic duct cannulation and external lymph&#xD;
      drainage for up to 7 days in adult surgical intensive care patients.&#xD;
&#xD;
      To explore other biochemical and physiological endpoints that can be used for the design of&#xD;
      future randomized controlled trials and estimate effect size of external drainage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional cohort study that will involve external drainage of thoracic duct&#xD;
      lymph in Surgical ICU patients with septic shock. The lymph drainage will continue for up to&#xD;
      a maximum of 7 days and will be continued in those interventional group patients discharged&#xD;
      from ICU back to the ward before that time. The lymph (and time-matched blood) will be&#xD;
      periodically sampled to detect changes in composition which will be correlated with changes&#xD;
      in disease severity and outcomes, as well as patient physiology and biochemistry. This pilot&#xD;
      study is not powered to detect changes in hospital/ICU stay, major complications or&#xD;
      mortality. The primary endpoint of interest is the pro-inflammatory cytokine profile and&#xD;
      concentrations in lymph and peripheral blood.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in circulating pro-inflammatory cytokines</measure>
    <time_frame>over 7 days of drainage</time_frame>
    <description>serial assays of lymph and plasma to measure inflammatory cytokines</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Thoracic Duct Drainage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is the main study group of patients with thoracic duct drainage</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thoracic duct drainage</intervention_name>
    <description>drain placement into the thoracic duct</description>
    <arm_group_label>Thoracic Duct Drainage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (18-80 years) patients in Surgical ICU with suspected or documented infection on&#xD;
             antibiotics and septic shock defined as hypotension requiring vasopressor therapy to&#xD;
             maintain MAP &gt; 65mmHg (modified from Sepsis-35).&#xD;
&#xD;
        Participants will fulfill the inclusion criteria not only at recruitment and consent, but&#xD;
        also be confirmed to still meet those criteria immediately prior to transfer to IR for the&#xD;
        procedure.&#xD;
&#xD;
        The patient will not be recruited if he or she no longer meet these criteria.&#xD;
&#xD;
        Patients experiencing hemodynamic instability, defined as (1) MAPs &lt; 65 despite ongoing&#xD;
        up-titration of pressors and volume resuscitation or (2) active titration of vasopressors&#xD;
        (more than 2 increases in past hour) or active volume resuscitation (more than 1-liter&#xD;
        bolus in past hour) that precludes travel to IR during the intervention window will be&#xD;
        excluded from the study and considered screen fails&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Open abdomen&#xD;
&#xD;
          2. Intra-abdominal sepsis preventing access to the lymphatic system&#xD;
&#xD;
          3. Prior instrumentation of the lymphatic system&#xD;
&#xD;
          4. Known occlusion of the left subclavian vein&#xD;
&#xD;
          5. Known malformation of the lymphatic system&#xD;
&#xD;
          6. Previous left axillary node dissection Â± left upper limb lymphoedema&#xD;
&#xD;
          7. Class 4 heart failure&#xD;
&#xD;
          8. Any chronic medical condition for which the patient is expected to have &lt;6-month&#xD;
             survival&#xD;
&#xD;
          9. Decompensated liver failure with ascites&#xD;
&#xD;
         10. Portal hypertension with history of variceal bleeding&#xD;
&#xD;
         11. Severe allergy to contrast agents&#xD;
&#xD;
         12. Need for continuous anticoagulation (that cannot be stopped for procedure)&#xD;
&#xD;
         13. Uncorrectable coagulopathy or INR &gt;1.5&#xD;
&#xD;
         14. Uncorrectable thrombocytopenia (platelet count less than 50,000)&#xD;
&#xD;
         15. Immunocompromised state (active cytotoxic chemotherapy or transplant recipient)&#xD;
&#xD;
         16. Pregnancy&#xD;
&#xD;
         17. DNR ('do not resuscitate') status&#xD;
&#xD;
         18. Subject or authorized representative not willing to provide consent (unconscious&#xD;
             patient will need to countersign prior to analysis of samples)&#xD;
&#xD;
         19. Unable to have central venous line or arterial line in place&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels D Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Niels D Martin, MD</last_name>
    <phone>215-662-7323</phone>
    <email>niels.martin@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joy Steele, RN</last_name>
    <phone>215-662-7323</phone>
    <email>joy.steele@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Niels D Martin, MD</last_name>
      <phone>215-662-7323</phone>
      <email>niels.martin@pennmedicine.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joy Steele, RN</last_name>
      <phone>215-662-7323</phone>
      <email>joy.steele@pennmedicine.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Niels D Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2021</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inflammatory cytokines</keyword>
  <keyword>Lymphatic drainage</keyword>
  <keyword>thoracic duct</keyword>
  <keyword>Sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

